Edition:
United States

Biotechnology & Medical Research

Page 2

Sprint Bioscience Q4 operating result swings to profit of SEK 2.7 mln

2:30am EST

Sprint Bioscience AB : Q4 revenue 13.0 million Swedish crowns ($1.5 million) versus 5.8 million crowns year ago .Q4 operating profit 2.7 million crowns versus loss 4.0 million crowns year ago.

Quintilesims intends to raise 850 mln euros through offering

2:30am EST

Quintiles Ims Holdings Inc : Quintilesims announces offering of senior notes and proposed refinancing of existing indebtedness .Intends to raise 850 million euros in gross proceeds through an offering of senior notes due 2025.

Viking Global Investors reports 7.8 pct passive stake in Calithera Biosciences

Tuesday, 21 Feb 2017 05:27pm EST

Calithera Biosciences Inc :Viking Global Investors Lp reports a 7.8 percent passive stake in Calithera Biosciences Inc as of Feb 8, 2017 - sec filing.

Versartis Q4 loss per share $0.64

Tuesday, 21 Feb 2017 04:05pm EST

Versartis Inc : Versartis reports fourth quarter 2016 financial results . Q4 loss per share $0.64 .Q4 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.

Ironwood pharmaceuticals qtrly loss per share $0.09

Tuesday, 21 Feb 2017 04:01pm EST

Ironwood Pharmaceuticals Inc : Qtrly loss per share $0.09 . Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million. . Qtrly non-gaap loss per share $0.12 . Ironwood Pharmaceuticals Inc - expects combined allergan and ironwood total 2017 marketing and sales expenses for linzess to be in range of $250 million to $280 million . Q4 earnings per share view $-0.24, revenue view $76.9 million -- Thomson Reuters I/B/E/S .Expects to use less than $100 million in cash for operations in 2017.

Global Blood Therapeutics announces proposed public offering of common stock

Tuesday, 21 Feb 2017 04:01pm EST

Global Blood Therapeutics Inc : Global Blood Therapeutics announces proposed public offering of common stock . Says agreement to sell $75.00 million in shares of its common stock in a registered underwritten public offering . Intends to use net proceeds from offering for development relating to its lead product candidate GBT440 .In addition, GBT has granted underwriter a 30-day option to purchase up to $11.25 million in shares of its common stock.

Oncogenex Pharmaceuticals says clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated

Tuesday, 21 Feb 2017 09:00am EST

Oncogenex Pharmaceuticals Inc : Oncogenex Pharmaceuticals, Inc. announces phase 2 apatorsen data for two clinical trials presented at the American Society Of Clinical Oncology (asco) 2017 genitourinary cancers symposium .Oncogenex Pharmaceuticals Inc- clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated.

Albany Molecular Research enters into agreement with pharmaceutical group Ferrer, Accord Healthcare

Tuesday, 21 Feb 2017 08:05am EST

Albany Molecular Research Inc : Albany Molecular Research Inc - entered into an agreement with pharmaceutical group Ferrer and Accord Healthcare, Inc. . Albany Molecular - agreement to develop, manufacture undisclosed complex parenteral drug product for registration, subsequent commercialization in u.s. . Albany molecular - under terms, amri to work with ferrer to develop, initially provide cgmp manufacturing, analytical support for registration of new product .Albany molecular research inc - accord healthcare to be responsible for advancing product candidate through regulatory submission, commercialization.

Neovacs and Biosense sign option agreement worth up to €65 million plus royalties

Tuesday, 21 Feb 2017 08:00am EST

Neovacs SA : Neovacs and Biosense sign option agreement worth up to €65 million plus royalties for Chinese development and commercial rights to ifnα kinoid for lupus and dermatomyositis . Neovacs SA - Neovacs receives an upfront fee and is eligible for additional milestone payments and double-digit sales royalties . Neovacs SA - Biosense receives option for development, commercial rights to ifnα kinoid for lupus and dermatomyositis in China, other selected territories . Neovacs SA - upon completion of Neovacs' ongoing Phase IIB trial for ifnα kinoid in lupus biosense will receive commercial rights for ifnα kinoid . Neovacs SA - Biosense will fund a Phase III clinical trial for ifnα kinoid in China . Neovacs SA - Biosense will bear all costs associated with these development and regulatory-related initiatives . Neovacs SA - Biosense receives first right of refusal in agreed upon asian markets for any further ifnα kinoid indications, including type 1 diabetes .Neovacs SA - additional terms were not disclosed.

Cidara Therapeutics reports unfavorable results of Phase 2 radiant trial of CD101 topical in VVC

Tuesday, 21 Feb 2017 07:30am EST

Cidara Therapeutics Inc : Cidara Therapeutics reports unfavorable results of Phase 2 radiant trial of CD101 topical in VVC . Cidara Therapeutics Inc - further development of CD101 topical for VVC to be discontinued . Cidara Therapeutics Inc says further development of CD101 topical for VVC to be discontinued . Cidara Therapeutics Inc - CD101 IV development program in Candidemia and invasive Candidiasis continuing and remains on track .Cidara Therapeutics Inc says CD101 gel and ointment were well-tolerated.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary